Aurobindo Pharma’s wholly owned subsidiary -- Auro Pharma has approved the acquisition of non-oncology prescription formulations business (the Business) of Khandelwal Laboratories on a going concern basis through a Business Transfer Agreement (BTA). The acquisition of the aforesaid Business shall add further brands in pain management and anti-infective which shall complement the existing product portfolios of the company and help in expanding its business in domestic market. The Business has around 470 people strong field force and has more than 1600 stockists and other distribution related infrastructure.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.